3 Biotech Stocks To Watch As US Policy Support Comes Into Focus

Simply Wall St.11-10 17:24

Biotech just walked into the policy spotlight, with BIO’s new BioAdvance blueprint putting faster trials, friendlier regulation and bigger federal research budgets on the table. That kind of attention...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682360032?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-10 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682360032","market":"sg","top_or_hot":-1,"title":"3 Biotech Stocks To Watch As US Policy Support Comes Into Focus","media":"Simply Wall St.","content":"<div>\n<p>Biotech just walked into the policy spotlight, with BIO’s new BioAdvance blueprint putting faster trials, friendlier regulation and bigger federal research budgets on the table. That kind of attention...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/3-biotech-stocks-to-watch-as-us-policy-support-comes-into-fo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks To Watch As US Policy Support Comes Into Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks To Watch As US Policy Support Comes Into Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-10 17:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/3-biotech-stocks-to-watch-as-us-policy-support-comes-into-fo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech just walked into the policy spotlight, with BIO’s new BioAdvance blueprint putting faster trials, friendlier regulation and bigger federal research budgets on the table. That kind of attention...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/3-biotech-stocks-to-watch-as-us-policy-support-comes-into-fo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/3-biotech-stocks-to-watch-as-us-policy-support-comes-into-fo","article_id":"2682360032","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/3-biotech-stocks-to-watch-as-us-policy-support-comes-into-fo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682360032","pubTimestamp":1794302658,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 10, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","VRTX":"福泰制药","SG9999015978.USD":"利安颠覆性创新基金A","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","BK4578":"CAR-T","BMED":"iShares Health Innovation Active ETF","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BIB":"Ultra纳斯达克生物科","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","GILD":"吉利德科学","IBB":"生物科技指数ETF-iShares Nasdaq","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","GNMX":"Corgi Genomics & Precision Medicine ETF","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","TMED":"T. Rowe Price Health Care ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK4581":"高盛持仓","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BBH":"VanEck Biotech ETF","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","MEDI":"HARBOR HEALTH CARE ETF","XBI":"SPDR S&P Biotech ETF","BK4585":"ETF&股票定投概念","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BIIB":"渤健公司"},"translate_title":"随着美国政策支持成为焦点，值得关注的 3 只生物技术股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMED":0.6,"MEDI":0.6,"IDNA":0.6,"TBXU":0.6,"XBI":1.5,"GNMX":0.6,"PBE":0.6,"VRTX":1,"TMED":0.6,"BIB":0.6,"IBB":0.6,"BIIB":1,"IBBQ":0.6,"GILD":1,"BBH":0.6},"content_text":"Biotech just walked into the policy spotlight, with BIO’s new BioAdvance blueprint putting faster trials, friendlier regulation and bigger federal research budgets on the table. That kind of attention can shift how capital flows, which means investors risk missing the early moves if they wait for the dust to settle. This article introduces 3 U.S.-listed biotech stocks that are directly exposed to this policy story and explains why that matters in the current environment. The three stocks covered below are just a sample, and the broader screen surfaced 51 more U.S.-listed biotechnology companies with similarly rich stories across gene and cell therapy, antibodies and small molecule platforms that are not discussed here. To spot ideas that fit your own risk tolerance and timing, head straight into the U.S.-listed Biotechnology Stocks screener to filter, analyze and identify the biotech setups that match your highest conviction. AdvertisementBiogen (BIIB) Overview: Biogen is a U.S.-listed biotechnology group focused on central nervous system and neurological diseases, using antibodies and other drug modalities to develop and commercialize therapies worldwide. Operations: Biogen reports about US$10.3b from discovering, developing and delivering therapies, with roughly US$6.3b recorded in the United States and the balance through segment adjustments. Market Cap: US$36.7b Biogen matters for this U.S.-listed Biotechnology Stocks theme because it sits where policy, clinical trial design and complex neurology drugs all intersect, and the analyst consensus Narrative on Simply Wall St describes how that mix shapes expectations for its next phase. \"Expansion of the Alzheimer’s franchise through LEQEMBI IQLIK in the US and LEQEMBI Pen in Japan, both once-weekly subcutaneous options for at-home administration, is expected to make treatment more accessible and convenient, which can widen the treated population and support higher long-term revenue and operating leverage.\"What happens to Biogen’s earnings profile if a single pressure on its broader neurology pipeline plays out differently than consensus assumes? If that earnings swing matters to your thesis, read the full narrative for Biogen to see how those pipeline scenarios could be accelerating or quietly stalling Biogen’s story. NasdaqGS:BIIB Earnings & Revenue History as at Nov 2026 Gilead Sciences (GILD) Overview: Gilead Sciences is a large U.S.-listed biopharmaceutical group that researches, develops and sells antiviral, oncology and immunology therapies closely tied to U.S. biotech regulation. Operations: Gilead generates about US$31b from discovering, developing and commercializing medicines, including roughly US$22.8b in the United States and US$4.8b in Europe. Market Cap: US$207b Gilead Sciences sits right where the BioAdvance policy blueprint is aimed, with a heavy U.S. R&D footprint and a portfolio that lives or dies on how regulators treat complex biologics, which is exactly why kapirey, an investor in the Simply Wall St Community, frames the story through one flagship program. \"Lenacapavir: First twice‑yearly HIV PrEP injectable; structural shift from daily oral to long‑acting → large TAM expansion and a key driver of HIV growth into the next decade\"What happens to Gilead’s cash generation and balance sheet flexibility if a single policy shift around long-acting HIV prevention changes pricing power. That kind of policy shock can flip the script fast. Read the full narrative for Gilead Sciences to see how Gilead Sciences could be accelerating or stalling beneath the headlines. NasdaqGS:GILD Earnings & Revenue Growth as at Nov 2026 Vertex Pharmaceuticals (VRTX) Overview: Vertex Pharmaceuticals develops specialty medicines for serious diseases such as cystic fibrosis, sickle cell disease, beta thalassemia, kidney disorders and pain. Operations: Vertex Pharmaceuticals generates about US$13b from pharmaceuticals, with around US$8.1b in the United States and US$3.8b in Europe. Market Cap: US$138.7b Vertex Pharmaceuticals is a pure-play biotech tied closely to U.S. drug policy. The analyst consensus Narrative on Simply Wall St highlights how its expanding portfolio of cell, gene and small molecule programs aligns with the kind of FDA and NIH support BioAdvance is trying to promote. \"Expansion of the renal disease portfolio, including late stage programs like povetacicept in IgA nephropathy with what management describes as best in class numerical reductions in proteinuria and favorable auto injector dosing, and inaxaplin in APOL1 mediated kidney disease with significant UACR reductions and an interim 1 year eGFR readout planned in early 2027, is supported by growing regulatory acceptance of proteinuria and 1 year eGFR endpoints.\"The real swing factor is what happens to that carefully built earnings profile if one key regulatory assumption in this toolkit shifts unexpectedly. If that kind of policy jolt is on your mind, read the full narrative for Vertex Pharmaceuticals to see where Vertex Pharmaceuticals could be accelerating or quietly decoupling expectations. NasdaqGS:VRTX Earnings & Revenue Growth as at Nov 2026 Seeking Alternatives Before The Crowd? Fresh ideas move first. Breakout themes gather momentum while screens are still quiet and under the radar for now. Do not get caught reacting late; consider acting earlier.  Track stronger balance sheets before momentum goes flying by using the list of solid balance sheet and fundamentals (25 results), which highlights companies with sturdier finances while it still matters. Target income plays that could keep paying even when markets wobble through the 6 dividend fortresses, curated for yield-focused investors who want to avoid chasing dropping payouts. Hunt for potential infrastructure participants in AI-related activity with the 53 AI infrastructure stocks, while many of these operators remain under the radar for now.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682360032","isCrawlerRequest":true}